In a planned interim analysis of a randomized phase IIb trial of the MHCI peptide, E75 (HER2 369-377), + GM-CSF (NeuVax) + trastuzumab versus GM-CSF + trastuzumab to prevent recurrences in node positive (NP) and/or triple negative (TNBC), HER2 low-expressing breast cancer patients we demonstrated a significant disease free survival (DFS) benefit specifically in triple negative (TNBC) patients to NeuVax + trastuzumab. Here, ERBB2 is linked to breast carcinoma.